

Neurotrophic Keratitis

Zaina Al-Mohtaseb, MD
Associate Professor/Associate Residency Director
Baylor College of Medicine
Southern Eye Congress 2022



Baylor
College of
Medicine

Financial Disclosure

- I have the following financial interests or relationships to disclose:
 - Zeiss
 - Alcon
 - Allergan
 - CorneaGen
 - Novartis
 - Visus
 - Tarsus
 - AcuFocus
 - Dompe






Baylor
College of
Medicine

Introduction

- NK is a degenerative corneal disease caused by impairment of trigeminal innervation
- Leads to decreased corneal sensation and subsequent epithelial keratopathies, epithelial defects, stromal ulceration and thinning, and, in severe cases, perforation^[a]
- incidence of < 5 per 10,000 people^[a,b]
- Underdiagnosed
- Often clinically silent until advanced stages

Baylor
College of
Medicine

Cornea Homeostasis



CORNEAL NERVE FIBERS

- Release neuromediators including acetylcholine, substance P (SP) and calcitonin gene-related peptide (CGRP) that provide trophic support to the ocular surface, stimulate wound healing, & maintain anatomic integrity
- When corneal sensory nerves are damaged, there is impaired corneal physiological renewal/healing
- May lead to epithelial breakdown with a poor tendency to heal



<https://www.nature.com/articles/s41467-019-09331-6>: new mechanics effects on cornea differentiation
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3010187/>: cell migration, cell proliferation, re-stratification, as well as matrix deposition and tissue remodeling. Particularly critical are cell migration and proliferation, which are driven by growth factors released coordinately into the injury sites





Fig. 8. A summary of common causes of neurotrophic corneal diseases.

Müller LJ, Marfurt CF, Kruse F, Tervo TM. Corneal nerves: structure, contents and function. *Exp Eye Res.* 2003 May;76(5):521-42. doi: 10.1016/s0014-4835(03)00050-2. Erratum in: *Exp Eye Res.* 2003 Aug;77(2):253. PMID: 12697417.
 Courtesy of Pflugfelder, MD




Neurotrophic Keratopathy

- Infectious
 - Herpes zoster, herpes simplex
 - Leprosy
- Toxic
 - Chemical/physical burns
 - Topical anesthetic abuse/chronic use of BAK drops
- Traumatic/Surgical/Iatrogenic
 - 5th nerve palsies (Surgery, Neoplasia, Aneurysm, Facial trauma, strokes)
 - CL use, retina lasers, LASIK
- Systemic Disease
 - Vitamin A deficiency
 - Diabetes mellitus
- Corneal Dystrophies



Staging (Mackie Classification)



Baylor
College of
Medicine

Stage	Clinical photo	Description of signs
1		Decreased TBUT Superficial PEE Gauze spots Irregular epithelium Superficial stromal haze
2		Persistent epithelial defect Descemet's folds AC inflammation
3		Corneal ulceration with stromal loss Stromal thinning with risk of perforation


CULLEN EYE
INSTITUTE

Jabbour S, Ashton C, Balal S, Kaye A, Ahmad S. The management of neurotrophic keratitis. *Curr Opin Ophthalmol.* 2021 Jul 1;32(4):362-368. doi: 10.1097/ICU.0000000000000766. PMID: 33966014.

Baylor
College of
Medicine


Diagnosis

- Symptoms > clinical signs
- No improvement with traditional methods
- Decreased blink rate
- Corneal aesthesiometer (Cochet-Bonnet) vs. Cotton Tip vs. Dental Floss
 - No drops; unilateral vs. bilateral
- Appearance of epithelium




Baylor
College of
Medicine

Neurotrophic Keratopathy Treatment






Case Presentation




Blood Products

- Contain same biologically active constituents as tears
 - TGF- β , IL 13, Lactoferrin, EGF, Vit A, NGF
- Serum tears are plasma tears devoid of clotting factors like fibrinogen
- Plasma rich blood growth factors (PRGF)
 - Higher concentration of platelet factors & more effective compared to serum tears
 - FDA approved kit



Case Presentation




Amniotic Membrane

- Has anti-inflammatory, anti-scarring, and anti-angiogenic effects
- Maintains limbal niche cells to support the quiescence of limbal epithelial stem cells toward regeneration



Amniotic Membrane



Case series: Extended wear of rigid gas permeable scleral contact lenses for the treatment of persistent corneal epithelial defects.

Khan M¹, Manuel K¹, Vegas B¹, Yadav S¹, Hemmati R¹, Al-Mohtaseb Z².

Author information

- 1 Cullen Eye Institute, Department of Ophthalmology, Baylor College of Medicine, Houston, Texas, USA.
- 2 Cullen Eye Institute, Department of Ophthalmology, Baylor College of Medicine, Houston, Texas, USA. Electronic address: zaina@bcm.edu.

Abstract

OBJECTIVES: To report the successful treatment of persistent corneal epithelial defects that failed to respond to alternative treatment methods using extended wear of three different rigid gas-permeable scleral lenses.

METHODS: Eight eyes of eight patients with persistent corneal epithelial defects were treated with Blanchard Onefit 2.0 Scleral lens, BostonSight Scleral lens, and BostonSight PROSE device and were observed for defect resolution and improvement in best-corrected visual acuity over the duration of treatment.

RESULTS: All eyes observed complete re-epithelialization with a mean time of 11.1 ± 5.5 days. At the conclusion of the treatment, visual acuity improved in all but one patient. No complications were observed during treatment.






CONCLUSIONS: Scleral lenses provide the corneal epithelium with hydration, oxygen permeation, and protection from mechanical forces; thereby facilitating healing of persistent corneal epithelial defects. This case series demonstrates the successful use of continuous wear scleral lenses in a number of patients for the treatment of persistent epithelial defects refractory to other interventions.

Copyright © 2018 British Contact Lens Association. Published by Elsevier Ltd. All rights reserved.




Surgical placement of frozen AMT

- Good option for management of perforations and pending perforations to delay need for keratoplasty.




Delay or Avoid Transplantation in Neurotrophic Ulceration



CULLEN EYE
INSTITUTE

Baylor
College of
Medicine

POM#1



CULLEN EYE
INSTITUTE

Baylor
College of
Medicine

POM#3 s/p PROSE





CULLEN EYE
INSTITUTE

Baylor
College of
Medicine

Scleral Lenses Eye Print PRO


- EyePrintPRO™ is a prosthetic scleral cover shell which improves vision by creating a new, smooth, refractive surface for the eye
- Impression is taken with a proprietary polymer that captures the precise curvatures of the entire ocular surface
- 3D scanned and a prosthetic scleral cover shell is designed around the surface irregularities



CULLEN EYE
INSTITUTE

Baylor
College of
Medicine

Eye Print PRO



CULLEN EYE
INSTITUTE

Baylor
College of
Medicine

Cont Lens Anterior Eye. 2019 Feb;42(1):117-122. doi: 10.1016/j.clae.2018.09.004. Epub 2018 Sep 25.

Case series: Extended wear of rigid gas permeable scleral contact lenses for the treatment of persistent corneal epithelial defects.

Khan M¹, Manuel K¹, Vegas B¹, Yadav S¹, Hemmati R¹, Al-Mohtaseb Z².

Author information

- 1 Cullen Eye Institute, Department of Ophthalmology, Baylor College of Medicine, Houston, Texas, USA.
- 2 Cullen Eye Institute, Department of Ophthalmology, Baylor College of Medicine, Houston, Texas, USA. Electronic address: zaina@bcm.edu.

Abstract

OBJECTIVES: To report the successful treatment of persistent corneal epithelial defects that failed to respond to alternative treatment methods using extended wear of three different rigid gas-permeable scleral lenses.

METHODS: Eight eyes of eight patients with persistent corneal epithelial defects were treated with Blanchard OneFit 2.0 Scleral lens, BostonSight Scleral lens, and BostonSight PROSE device and were observed for defect resolution and improvement in best-corrected visual acuity over the duration of treatment.

RESULTS: All eyes observed complete re-epithelialization with a mean time of 11.1 ± 5.5 days. At the conclusion of the treatment, visual acuity improved in all but one patient. No complications were observed during treatment.



CONCLUSIONS: Scleral lenses provide the corneal epithelium with hydration, oxygen permeation, and protection from mechanical forces; thereby facilitating healing of persistent corneal epithelial defects. This case series demonstrates the successful use of continuous wear scleral lenses in a number of patients for the treatment of persistent epithelial defects refractory to other interventions.

Copyright © 2018 British Contact Lens Association. Published by Elsevier Ltd. All rights reserved.

Baylor
College of
Medicine

PROSE

- PROSE: “prosthetic replacement of the ocular surface ecosystem”
- Diameter: 17.5-23mm
- Rests on bulbar conjunctiva
- Vaults cornea (no touch)
- Custom designed to treat distorted corneal surface or ocular surface disease




Baylor
College of
Medicine

Ocul Surf. 2018 Feb 6; pii: S1542-0124(17)30263-X; doi: 10.1016/j.jtos.2018.01.003. [Epub ahead of print]

Assessment of the Prosthetic Replacement of Ocular Surface Ecosystem (PROSE) scleral lens on visual acuity for corneal irregularity and ocular surface disease.

Parra A¹, Roth BM¹, Nguyen TM¹, Wang L¹, Pflugfelder SC¹, Al-Mohtaseb Z².

Improvement in Vision by Etiology



Baylor
College of
Medicine

Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy

A Multicenter Randomized Vehicle-Controlled Pivotal Trial



Stephen C. Pflugfelder, MD,¹ Mina Massaro-Giordano, MD,² Victor L. Perez, MD,³ Pedram Hamrah, MD,⁴ Sophie X. Deng, MD, PhD,⁵ Ladan Espandar, MD, MS,^{6,7} C. Stephen Foster, MD,^{8,9} John Affeldt, MD,¹⁰ John A. Seedor, MD,¹¹ Natalie A. Afshari, MD,¹² Wendy Chao, PhD,¹³ Marcello Allegretti, PhD,¹³ Flavio Mantelli, MD, PhD,¹³ Reza Dana, MD, MPH^{9,14}

Cenegermin (Oxervate)

- Recombinant human NGF (rhNGF) produced in Escherichia coli
- Developed based on studies with murine nerve growth factor (NGF)
- NGF0212/REPARO and NGF0214 trials demonstrated efficacy and safety
- NGF0214 showed statistically significant healing compared to control



Baylor
College of
Medicine







CULLEN EYE INSTITUTE

Baylor College of Medicine

Pre Oxervate


Post Oxervate

Photo courtesy of Stephen Pflugfelder, MD




CULLEN EYE INSTITUTE

Baylor College of Medicine



POM # 6 and post Oxervate



Corneal Neurotization

- Donor nerve graft is co-apted to the damaged nerve
- Transfer of a healthy nerve segment to the corneo-limbal area, reestablishing a basis for sub-basal plexus regeneration
- Corneal reinnervation can be performed by direct nerve transfers or by nerve graft interpositions




FIGURE 1: Direct Neurotization technique. The supraorbital (red line) or supraorbital/zygomatic (green line) nerves are harvested at the orbital rim through a bicoronal incision (blue line) and transferred (yellow line) under the nasal bridge to the contralateral orbital surface. They are secured under the conjunctiva in pockets using suture or fibrin glue (X). Some procedures have been reported to be done with bicoronal incision for ipsilateral nerves (X).




FIGURE 2: Indirect Neurotization technique. The supraorbital (red line) or supraorbital/zygomatic (green line) nerves are harvested at the orbital rim through a bicoronal incision (blue line). A graft (yellow line) is coapted to the proximal end of the nerve and then transferred under the nasal bridge and through another sub-brow incision (blue line) to the contralateral orbital surface. It is secured within conjunctiva (X).

Corneal Neurotization




Photo courtesy of Richard Allen, MD

Outcomes of corneal neurotization

- Most studies have reported a **subjective improvement at 6 months**
- Corneal **esthesiometry may lag behind**
 - Cochet–Bonnet esthesiometry was the method of choice in older children and adults
 - In children less than 2 years of age, esthesiometry was replaced with surrogate measures of corneal sensation notably corneal vascularization, ocular surface healing and decreased fluorescein uptake
- Studies note a period of **ocular pain and discomfort** after the procedure that is attributed to the **subjective sensory recovery** of the neurotized cornea. This usually **precedes the epithelial healing process**
- Evidence also suggests that only the **corneal nerves regenerate without the normal reflex mechanisms** involved with the trigeminal nerves. Catapano et al. reported absence of the blink reflex and minimal effect on lacrimal gland secretion even after full neurotization occurs



Baylor
College of
Medicine

Conclusions

- Many options for in office medical and surgical therapies for neurotrophic/exposure keratitis
- Medical options include serum tears/PRGF drops and therapeutic contact lenses
- Surgical options include amniotic membranes and tarsorrhaphies
- A combination of therapies is needed at times



Baylor
College of
Medicine

References

- Jabbour S, Ashton C, Balal S, Kaye A, Ahmad S. The management of neurotrophic keratitis. *Curr Opin Ophthalmol*. 2021 Jul 1;32(4):362-368. doi: 10.1097/ICU.0000000000000766. PMID: 33966014.
- Sacchetti M, Lambiase A. Diagnosis and management of neurotrophic keratitis. *Clin Ophthalmol*. 2014 Mar 19;8:571-9. doi: 10.2147/OPHT.S45921. PMID: 24672223; PMCID: PMC3964170.
- Müller LJ, Marfurt CF, Kruse F, Tervo TM. Corneal nerves: structure, contents and function. *Exp Eye Res*. 2003 May;76(5):521-42. doi: 10.1016/s0014-4835(03)00050-2. Erratum in: *Exp Eye Res*. 2003 Aug;77(2):253. PMID: 12697417.
- Chapter-003 The Human Cornea: Basic Structure and Function BOOK TITLE: [Copeland and Afshari's Principles and Practice of Cornea \(2 Volumes\)](#)
- <https://www.nature.com/articles/s41467-019-09331-6>: new mechanics effects on cornea differentiation
- <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3010187/>: cell migration, cell proliferation, re-stratification, as well as matrix deposition and tissue remodeling. Particularly critical are cell migration and proliferation, which are driven by growth factors released coordinately into the injury sites
- Central stem cells: <https://ovs.arvojournals.org/article.aspx?articleid=2164151>
- <https://www.sciencedirect.com/science/article/abs/pii/S1542012420301476>
- <https://www.sciencedirect.com/science/article/pii/S0014483518302082>
- Nagano T, Nakamura M, Nakata K, et al. Effects of substance P and IGF-1 in corneal epithelial barrier function and wound healing in a rat model of neurotrophic keratopathy. *Invest Ophthalmol Vis Sci*. 2003;44(9):3810-3815.
- Bremond-Gignac D, Darulich A, Robert MP, et al. Recent innovations with drugs in clinical trials for neurotrophic keratitis and refractory corneal ulcer. *Expert Opin Investig Drugs*. 2019;1013-1020.
- a. Bremond-Gignac D, Darulich A, Robert MP, et al. Recent innovations with drugs in clinical trials for neurotrophic keratitis and refractory corneal ulcer. *Expert Opin Investig Drugs*. 2019;1013-1020.
- b. Sosne G. Thymosin beta 4 and the eye: the journey from bench to bedside. *Expert Opin Biol Ther*. 2018 Jul;18(sup1):99-104. doi: 10.1080/14712598.2018.1486818. PMID: 30063853.
- c. ClinicalTrials.gov. NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Chemical and/or Thermal Injuries (EXPEDE). <https://clinicaltrials.gov/ct2/show/NCT04081103>. Updated August 26, 2020. Accessed November 24, 2020.
- d. Nagano T, Nakamura M, Nakata K, et al. Effects of substance P and IGF-1 in corneal epithelial barrier function and wound healing in a rat model of neurotrophic keratopathy. *Invest Ophthalmol Vis Sci*. 2003;44(9):3810-3815.
- e. ClinicalTrials.gov. Efficacy and Safety of Plasma Rich in Growth Factors (PRGF-Endoret) Eye-drops in the Treatment of Neurotrophic Keratitis. <https://clinicaltrials.gov/ct2/show/NCT02707120>. Updated July 14, 2017. Accessed November 24, 2020.
- Wolkow N, Habib LA, Yoon MK, Freitag SK. Corneal Neurotization: Review of a New Surgical Approach and Its Developments. *Semin Ophthalmol*. 2019;34(7-8):473-487. doi: 10.1080/08820538.2019.1648692. Epub 2019 Aug 1. PMID: 31370735.
- Koalk M, Baig K. Corneal neurotization. *Curr Opin Ophthalmol*. 2019 Jul;30(4):292-298. doi: 10.1097/ICU.0000000000000578. PMID: 31033738.
- Solyman O, Elhusseiny AM, Ali SF, Allen R. A Review of Pediatric Corneal Neurotization. *Int Ophthalmol Clin*. 2022 Jan 1;62(1):83-94. doi: 10.1097/IO.0000000000000403. PMID: 34965228.



Baylor
College of
Medicine

Thank you!
zaina1225@gmail.com

